Vnitr Lek 2021, 67(4):244-248 | DOI: 10.36290/vnl.2021.060

An effective communication between the physician and the patient in an early intervention of hypertension and dyslipidemia

Barbora Nussbaumerová
Centrum preventivní kardiologie, II. interní klinika LF a FN v Plzni, UK v Praze

The article summarizes the cornestones of inicitating the pharmacotherapy of hypertension and dyslipidemia. The intervention of dyslipidemia should not be delayed after the intervention of hypertension. The compliance and the adhrence are far from ideal. The physicians should support their patients with an appropriate approach. Vascular age should be used for the explanation of the cardiovascular risk.

Keywords: hypertension, dyslipidemia, comunication, compliance, adherence, vascular age.

Published: June 29, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Nussbaumerová B. An effective communication between the physician and the patient in an early intervention of hypertension and dyslipidemia. Vnitr Lek. 2021;67(4):244-248. doi: 10.36290/vnl.2021.060.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021-3104. Go to original source... Go to PubMed...
    2. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modifi cation to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111-188. Go to original source... Go to PubMed...
    3. Böhm M, Schumacher H, Laufs U et al. Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. Am Heart J 2013; 166(2): 306-314.e7. doi: 10.1016/j.ahj.2013.04.016. Go to original source... Go to PubMed...
    4. Mazzaglia G, Ambrosioni E, Alacqua M et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation 2009; 120(16): 1598-1605. doi: 10.1161/CIRCULATIONAHA.108.830299. Go to original source... Go to PubMed...
    5. Ference BA, Bhatt DL, Catapano AL, et al. Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. JAMA. 2019; 322(14): 1381-1391. Go to original source... Go to PubMed...
    6. Olsen MH, Angell SY, Asma S et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet. 2016; 388(10060): 2665-2712. Go to original source... Go to PubMed...
    7. Zafarová Z. Zaznělo na 18. kongrese Medicíny pro praxi, Olomouc, 25.-26. září 2020 Využijme cévní věk k motivaci pacientů k preventivní kardiovaskulární léčbě. Med. praxi 2020; 17(5): 336-338. Go to original source...
    8. Češka R, Petrák O. Vaskulární věk, Vnitř Lék 2019; 65(12): 770-774. Go to original source...
    9. Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur Heart J. 2010t; 31(19): 2351-2358. Go to original source... Go to PubMed...
    10. Lopez-Gonzalez AA, Aguilo A, Frontera M, et al. Eff ectiveness of the Heart Age tool for improving modifi able cardiovascular risk factors in a Southern European population: a randomized trial. Eur J Prev Cardiol. 2015; 22(3): 389-396. Go to original source... Go to PubMed...
    11. Cuende JI. Vascular Age Versus Cardiovascular Risk: Clarifying Concepts Rev Esp Cardiol. 2016; 69(3): 243-246. Go to original source... Go to PubMed...
    12. Bangalore S, Kamalakkannan G, Parkar S et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120: 713-719. Go to original source... Go to PubMed...
    13. Motlová L, Holub D. Compliance a adherence: spolupráce při léčbě. Remedia 2005(6).

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.